This PDF is the current document as it appeared on Public Inspection on 01/10/2014 at 08:45 am.
Department of the Army, DoD.
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/761,942, entitled “Anti-Filovirus Therapeutics,” filed on February 7, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.Start Further Info
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.End Further Info End Preamble Start Supplemental Information
The invention relates to an antisense oligonucleotide directed to a mRNA encoding a mammalian Niemann-Pick C1 (NPC1) receptor, and combinations thereof and compositions comprising such are provided. Also provided are methods of treating or reducing filovirus infection of a subject.Start Signature
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2014-00290 Filed 1-10-14; 8:45 am]
BILLING CODE 3710-08-P